The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
PBPK models for the prediction of in vivo performance of oral dosage forms
Abstract
Drug absorption from the gastrointestinal (GI) tract is a highly complex process dependent upon numerous factors including the physicochemical properties of the drug, characteristics of the formulation and interplay with the underlying physiological properties of the GI tract. The ability to accurately predict oral drug absorption during drug product development is becoming more relevant given the current challenges facing the pharmaceutical industry. Physiologically-based pharmacokinetic (PBPK) modeling provides an approach that enables the plasma concentration-time profiles to be predicted from preclinical in vitro and in vivo data and can thus provide a valuable resource to support decisions at various stages of the drug development process. Whilst there have been quite a few successes with PBPK models identifying key issues in the development of new drugs in vivo, there are still many aspects that need to be addressed in order to maximize the utility of the PBPK models to predict drug absorption, including improving our understanding of conditions in the lower small intestine and colon, taking the influence of disease on GI physiology into account and further exploring the reasons behind population variability. Importantly, there is also a need to create more appropriate in vitro models for testing dosage form performance and to streamline data input from these into the PBPK models. As part of the Oral Biopharmaceutical Tools (OrBiTo) project, this review provides a summary of the current status of PBPK models available. The current challenges in PBPK set-ups for oral drug absorption including the composition of GI luminal contents, transit and hydrodynamics, permeability and intestinal wall metabolism are discussed in detail. Further, the challenges regarding the appropriate integration of results from in vitro models, such as consideration of appropriate integration/estimation of solubility and the complexity of the in vitro release and precipitation data, are also highlighted as important steps to advancing the application of PBPK models in drug development. It is expected that the "innovative" integration of in vitro data from more appropriate in vitro models and the enhancement of the GI physiology component of PBPK models, arising from the OrBiTo project, will lead to a significant enhancement in the ability of PBPK models to successfully predict oral drug absorption and advance their role in preclinical and clinical development, as well as for regulatory applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–209 of 209
Physiologically-Based Pharmacokinetics
Jamei, M., Yeo, K. R., Johnson, T. N., Ghobadi, C., Chetty, M., Abduljalil, K., Lu, G., Salem, F., Darwich, A. S., & Rostami‐Hodjegan, A. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0418-7_16 · Cited by 21
Self-citationMirza, T., Bykadi, S., Ellison, C. D., Yang, Y., Davit, B. M., & Khan, M. A. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0861-y · Cited by 20
Bergstrand, M., Söderlind, E., Eriksson, U. G., Weitschies, W., & Karlsson, M. O. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0594-3 · Cited by 20
Self-citationClaassen, K., Willmann, S., Eißing, T., Preußer, T., & Block, M. S. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00004 · Cited by 16
Watson, K. J., Davis, J. D., & Jones, H. M. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038224 · Cited by 15
Weber, O., Willmann, S., Bischoff, H., Li, V., Vakalopoulos, A., Lustig, K., Hafner, F., Heinig, R., Schmeck, C., & Buehner, K. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04064.x · Cited by 13
Gómez‐Mantilla, J. D., Casabó, V. G., Schaefer, U. F., & Lehr, C. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.11.008 · Cited by 13
Jones, H. M., Chan, P. L. S., van der Graaf, P. H., & Webster, R. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04047.x · Cited by 10
Polak, S., Jamei, M., Turner, D., Yang, J., Neuhoff, S., Gt, T., & Rostami‐Hodjegan, A. (2008) · Cited by 6
Self-citation
Cited by
The Role of Reactive Oxygen Species in Arsenic Toxicity
Hu, Y., Li, J., Lou, B., Wu, R., Wang, G., Lu, C., Wang, H., Pi, J., & Xu, Y. (2020) · Biomolecules · doi:10.3390/biom10020240 · Cited by 413
Berry, D. J., & Steed, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.003 · Cited by 406
Workgroup, E. M., Marshall, S., Burghaus, R., Cosson, V, Cheung, S., Chenel, M., DellaPasqua, O., Frey, N., Hamrén, B., Harnisch, L., et al. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12049 · Cited by 373
Boyd, B. J., Bergström, C. A. S., Vinarov, Z., Kuentz, M., Brouwers, J., Augustijns, P., Brandl, M., Bernkop-Schnürch, A., Shrestha, N., Préat, V., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.104967 · Cited by 367
Food, gastrointestinal pH, and models of oral drug absorption
Abuhelwa, A. Y., Williams, D. B., Upton, R. N., & Foster, D. J. R. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.11.034 · Cited by 349
Metadata
- Authors
- Kostewicz, E. S., Aarons, L., Bergstrand, M., Bolger, M. B., Galetin, A., Hatley, O., Jamei, M., Lloyd, R., Pepin, X., Rostami-Hodjegan, A., Sjögren, E., Tannergren, C., Turner, D. B., Wagner, C., Weitschies, W., & Dressman, J.
- Venue
- European Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 57
- Pages
- 300-321
- ISSN
- 0928-0987 (ISSN-L)
- OpenAlex
- W2115848859
- Cited by
- 315
- References
- 209
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.